Tracer library / [225Ac]Ac-PSMA-RLT

[225Ac]Ac-PSMA-RLT

Also written as [225Ac]Ac-PSMA-RLT
Radionuclide
Ac-225
Modality
—
Production route
—
Stage
—
Syntheses indexed
0
Prostate cancerCell proliferationPSMA-directed radioligand therapy

What it is

Compound class
PSMA-targeted radioligand (Ac-225 labelled)
Target / mechanism
Prostate specific membrane antigen (PSMA) PMID 37164814
Clinical application
Metastatic castration-resistant prostate cancer (mCRPC) PMID 39614800
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
    2023 · Clin Genitourin Cancer · Clinical study

Need this precursor?We can point you to suppliers for [225Ac]Ac-PSMA-RLT, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 37164814, 39614800.